Evonik recognized as a leading contract manufacturing organization for the pharma industry for the 5th consecutive year
- Recipient of 2022 CMO Leadership Awards
- Features in all six categories - Capabilities, Compatibility, Expertise, Quality, Reliability and Service
- Continued reliability and commitment to sustainability recognized by customers
Essen, Germany. Evonik is a winner of the CMO Leadership Awards for the fifth year running. Organized by the publications Life Science Leader and Outsourced Pharma, the awards highlight excellence in pharmaceutical contract manufacturing across six categories. The award supports Evonik’s leading position as one of the world’s largest contract development and manufacturing organizations (CDMO) for active pharmaceutical ingredients (APIs), intermediates and excipients.
Evonik Health Care is part of Nutrition & Care, the life sciences division at Evonik. As a cornerstone for the division’s growth trajectory, Evonik Health Care is driving the transition to a system solutions provider for leading life science companies.
Nutrition & Care aims to increase the share of system solutions from 20 percent today, to more than 50 percent by 2030.
“It is a tremendous honor to be selected for this award by our customers. We are grateful for the trust they place in us every day, allowing us to support them produce life-saving medicines for patients around the world,” said Thomas Riermeier, head of Evonik’s Health Care business line. “This award further validates our position as the industry’s preferred development and manufacturing partner, committed to continuous improvement for the benefit of customers and patients.”
Award winners are chosen through market research based on feedback from pharmaceutical and biopharmaceutical companies that use outsourcing services. For the 2022 CMO Leadership Awards, 86 CMOs were evaluated according to 23 performance metrics. Respondents only evaluated companies which they had worked with on an outsourced project over the past 18 months. For the fifth consecutive year, Evonik scored across all six categories: Capabilities, Compatibility, Expertise, Quality, Reliability and Service.
Evonik’s experience in the custom manufacturing of active pharmaceutical ingredients blends well with the company’s expertise in delivery technologies for complex oral and parenteral drug products. The combination of capabilities enables customers to benefit from an integrated portfolio of system solutions across the markets for drug substance, drug delivery and product.
Building on its extensive technological know-how in process design und industrialization, Evonik Health Care successfully set up the production of specialty lipids for the Pfizer/BioNTech Covid-19 vaccine at two sites in Germany in just eight weeks. This enabled the acceleration of vaccination campaigns all over the world.
With a network of sites based in Europe and the U.S., Evonik supports customers in selecting and supplying functional excipients, developing parenteral or oral formulations, and manufacturing finished drug products. In addition to this integrated portfolio of products and services, customers turn to Evonik for its reliability and commitment to sustainability in implementing complex synthesis projects.
Company information
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €12.2 billion and an operating profit (adjusted EBITDA) of €1.91 billion in 2020. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.
About Nutrition & Care
The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of around three billion euros in 2020 with about 5,300 employees.
Disclaimer
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.
